Claritas Pharmaceuticals, Inc. Stock

CLAZF

CA1806342061

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 04:16:04 28/02/26 am AEDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap	5.37M 3.79M 3.3M 3.06M 2.86M 357M 5.4M 36.28M 14.06M 176M 14.21M 13.91M 611M	P/E 2019	-0.74x	P/E 2020	0.13x
Enterprise Value	6.29M 4.44M 3.87M 3.58M 3.35M 419M 6.33M 42.49M 16.47M 206M 16.65M 16.29M 715M	EV / Sales 2019	-	EV / Sales 2020	-
Free-Float	99.74%	Yield 2019 *	-	Yield 2020	-

* Estimated data More valuation ratios

Chart: Claritas Pharmaceuticals, Inc.

Timeframe

Style

Dynamic Chart

Managers and Directors: Claritas Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Farrell CEO	Chief Executive Officer	76	21/06/2017
Victoria Rudman DFI	Director of Finance/CFO	58	29/06/2018

Director	Title	Age	Since
Robert Farrell CHM	Chairman	76	18/03/2021

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CLARITAS PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	37
LONZA GROUP AG	+1.44%	+1.71%	-10.98%	-6.19%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+310.97%	+534.70%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+9.34%	+41.02%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.43%	-21.94%	28B
CELLTRION, INC.	-1.90%	-1.56%	+10.24%	+21.21%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+48.76%	+104.27%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.08%	+4.79%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+98.13%	+80.47%	12.25B
Average	+0.37%	+0.66%	+60.00%	+94.79%	21.25B
Weighted average by Cap.	+0.77%	+1.27%	+65.47%	+110.06%

See all sector performances

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâ€™s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
CLAZF Stock

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

3 years	0		0
5 years	0		0.7
10 years	0		15.31

Date	Insider	Type	Quantity	% Market Cap.
11/10/21	Andrew Salzman	Buy	118,000	0.3332%
11/10/21	Andrew Salzman	Buy	152,500	0.4307%
11/10/21	Andrew Salzman	Buy	24,500	0.0692%

	2019	2020
Net sales	-	-
Net income	-21.21M -14.96M -13.05M -12.08M -11.31M -1.41B -21.34M -143M -55.55M -695M -56.16M -54.96M -2.41B	4.21M 2.97M 2.59M 2.4M 2.24M 280M 4.24M 28.45M 11.03M 138M 11.15M 10.91M 479M
Net Debt	704K 497K 433K 401K 375K 46.86M 708K 4.76M 1.84M 23.06M 1.86M 1.82M 80.08M	920K 649K 566K 524K 491K 61.23M 926K 6.22M 2.41M 30.14M 2.44M 2.38M 105M

Claritas Pharmaceuticals, Inc. Stock

Stocks

CLAZF

CA1806342061

Biotechnology & Medical Research

Valuation: Claritas Pharmaceuticals, Inc.

Chart: Claritas Pharmaceuticals, Inc.

Course Extremes

Managers and Directors: Claritas Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile